Labeling Changes Possible For HCV Direct-Acting Antivirals As EMA Probes HBV Reactivation
This article was originally published in SRA
Executive Summary
The European Medicines Agency has begun a review of the direct-acting antivirals (DAAs) for hepatitis C in light of a number of recent cases showing that hepatitis B virus has been reactivated in some HCV patients treated with the newer products1.